Infectious Diseases Clinical Research Consortium (IDCRC)
The Infectious Diseases Clinical Research Consortium (IDCRC) and Vaccine and Treatment Evaluation Units (VTEUs) work in tandem with the National Institute of Allergy and Infectious Diseases (NIAID) as a coordinated national and global network of scientific experts working to develop and test vaccines and other therapies to combat infectious diseases.
To find out, a IDCRC team at Kaiser Permanente Washington Health Research Institute, Seattle, and Emory University School of Medicine, Atlanta, expanded the initial Phase 1 trial to include 20 healthy volunteers ages 56 to 70 and another 20 healthy volunteers ages 71 and older.
The COVPN was established by merging four existing NIAID-funded clinical trials networks: the HIV Vaccine Trials Network; the HIV Prevention Trials Network; the Infectious Diseases Clinical Research Consortium; and the AIDS Clinical Trials Group. The COVPN announced two Phase 3 trials to determine whether monoclonal antibodies can prevent SARS-CoV-2, the virus that causes COVID-19.
Support of Clinical Research for 2019 Novel Coronavirus (SARS-CoV-2) & Disease (COVID-19)
The novel coronavirus 2019-nCoV, SARS-CoV-2, pandemic continues to expand and the IDCRC is working with NIAID to conduct clinical research into the treatment and prevention of infections (COVID-19) caused by this virus.
Two randomized, placebo-controlled clinical trials funded by the NIH are expanding enrollment to include the VTEU at NYU to further evaluate convalescent plasma as a treatment for patients hospitalized with COVID-19.
A Phase 1 trial of an investigational mRNA vaccine to prevent SARS-CoV-2 infection has shown that the vaccine is well-tolerated and generates a strong immune response in older adults. New England Journal of Medicine
An investigational vaccine designed to protect against COVID-19 resulted in production of both binding and neutralizing antibodies in healthy adult volunteers, according to interim results of an ongoing phase 1 trial published in the NEJM. The Phase 1 trial was led and supported by IDCRC sites.
The NIAID-sponsored, Infectious Diseases Clinical Research Consortium (IDCRC) and the nation’s Vaccine Trials and Evaluation Units (VTEUs) enrolled a quarter of all patients in this international study.
The IDCRC works through a flexible, sustaining structure to advance new countermeasures and approaches to product development, implement efficient clinical study/trial designs, and support exceptional career development and mentoring of future leaders in infectious diseases clinical research. The consortium's collective experience and access to diverse populations give it the ability to evaluate new vaccines and therapies for infectious diseases.
IDCRC Vaccine & Treatment Evaluation Units (VTEUs)
